Theissen P, Smolarz K, Scharl A, Groth A, Scheidhauer K, Voth E, Schicha H
Kliniken und Polikliniken für Nuklearmedizin, Universität zu Köln, FRG.
Nuklearmedizin. 1994 Aug;33(4):132-7.
To define the value of magnetic resonance imaging (MRI) in screening for bone metastases (BM) compared to bone scintigraphy (BSc) 102 patients with tumours with frequent BM were examined also by MRI of spine, pelvis, femora, and proximal tibiae. All patients had normal BSc and 96 (94%) normal MRI. Only 6% of the patients had focal abnormalities within the bone marrow. This indicates that there is a 94% probability of absence of BM if BSc is normal. Therefore, BSc should currently remain the method of choice for screening for BM. Despite MRI is sensitive and specific, with the common technique up to now it should not be used instead of BSc in screening because of costs, duration, and lack of whole body examination. MRI is a valuable adjunct in equivocal findings in BSc with negative results on radiographs.
为了确定与骨闪烁显像(BSc)相比,磁共振成像(MRI)在筛查骨转移瘤(BM)中的价值,对102例有频繁发生BM风险的肿瘤患者进行了脊柱、骨盆、股骨和胫骨近端的MRI检查。所有患者的BSc检查结果均正常,96例(94%)患者的MRI检查结果也正常。仅6%的患者骨髓内有局灶性异常。这表明,如果BSc检查结果正常,那么不存在BM的概率为94%。因此,目前BSc仍应作为筛查BM的首选方法。尽管MRI敏感且特异,但就目前的常用技术而言,由于成本、检查时间以及缺乏全身检查等原因,在筛查中不应替代BSc。在BSc检查结果不明确且X线片结果为阴性时,MRI是一种有价值的辅助检查手段。